Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".